Africa Pharmaceuticals Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The Middle East & Africa pharmaceutical market covers branded prescription drugs, generics, over-the-counter medicines, vaccines and biologics sold across both North Africa and Sub-Saharan Africa. It is currently estimated at around USD 31.087 billion in 2026, making it one of the smaller geographic markets globally but one of the faster-growing. South Africa, Egypt, Saudi Arabia, the UAE and Nigeria account for the largest revenue shares, while Sub-Saharan Africa as a sub-region is projected to reach roughly USD 13 billion by 2030.

The main engines of growth are demographic and epidemiological: a population of more than 1.4 billion people, a rising middle class, urbanization and a sharp increase in chronic non-communicable diseases layered on top of persistent infectious disease burdens. Public-sector health investment, expansion of national insurance schemes, and growing private healthcare capacity are widening access to medicines. At the same time, governments are actively trying to reduce import dependence by incentivizing local manufacturing and regulatory convergence.

By product type, prescription drugs hold the largest share, followed by OTC medicines, vaccines and dietary supplements; by molecule, small molecules continue to dominate while biologics and biosimilars are growing the fastest. By therapeutic area, infectious diseases, cardiovascular conditions, oncology, diabetes and respiratory illnesses lead demand. Geographically, North Africa and the Gulf Cooperation Council countries generate the bulk of revenue, while Sub-Saharan Africa offers the strongest growth rate, particularly Nigeria, Kenya, Ethiopia and Tanzania.

What are the recent trends and outlook?

Key forward-looking trends include deeper regulatory harmonization via the African Medicines Agency, accelerated local and intra-African vaccine and insulin manufacturing, and wider adoption of digital health, e-prescribing and telemedicine that expand medicine access in underserved areas. Biosimilars, advanced therapy medicinal products and preventive vaccines are expected to outpace the broader market. Looking ahead, the market is likely to sustain mid-single-digit annual growth through 2031 and beyond, with value increasingly captured by companies investing in local manufacturing, chronic-disease portfolios and digital distribution.